OPE	Please ty	pe a plus sign (+) inside this box —	•	+			#19
JUH S 6 S	Substitute	e for form 1449A/PTO			- <del></del>	Co	omplete if Known
ATENT & TRA	<b>E</b>					Application Number	09/972,035
ATEN	OFF	INFORMATION DISCL	.os	URE		Filing Date	October 4, 2001
PALS THE		STATEMENT BY APP	LIC	ANT		First Named Inventor	Daniel Albert WETTSTEIN
						Group Art Unit	1653
		(use as many sheets as ne	essa	) <u> </u>		Examiner Name	Myron HILL
	Sheet	1	of	1	1	Attorney Docket Number	1907.03

			ī	J.S. PATENT DOCUMENTS	,	
Examiner Initials'	Cite No. <sup>1</sup>	U.S. Patent Documents  Number Kind C (if know		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
AM	A1	US 2003/0049607		Greener et al.	03-13-2003	

				FO	REIGN PATENT DOCUMEN	rs		
Examiner	Cite	Fore	ign Patent D	ocuments	Name of Patentee or	Date of Publication	Pages, Columns, Lines, Where Relevant	
Initials'	No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Applicant of Cited Documents	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T <sup>6</sup>

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, volume-issue number(s), page(s), publisher, city and/or country where published.	T²
Pm.	B1	WHITTLE, Peter J., et al., "Protein Structure-Based Drug Design", Annu. Rev. Biophys. Biomol. Struct., 1994; 23:349-375	
	B2	MHASHILKAR, Abner M., et al., "Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1infection by anti-Tat single chain intrabodies", <i>The EMBO Journal</i> , 1995; 14(7):1542-1551	
	В3	HUANG, Mingjun, et al., "p6 <sup>Gag</sup> Is Required for Particle Production from Full-Length Human Immunodeficiency Virus Type 1 Molecular Clones Expressing Protease", <i>Journal of Virology</i> , November 1995; 69(11):6810-6818	
	В4	ROSSI, John J., "Therapeutic applications of catalytic antisense RNAs (ribozymes)", CIBA Foundation Symposium, 1997; 209:195-204	
RE	B5	LEVIN, Reuven, et al., "Inhibition of Early and Late Events of the HIV-1 Replication Cycle by Cytoplasmic Fab Intrabodies against the Matrix Protein, p17", <i>Molecular Medicine</i> , February 1997; 3(2):96-110	
C	В6	SAVARINO, Andrea, et al., "The Biochemistry of Gene Therapy for AIDS", Clin. Chem. Lab. Med., 1998; 36(4):205-210	
EIVE	В7	VERKHIVKER, Gennady M., "Towards understanding the mechanisms of molecular recognition by computer simulations of ligand-protein interactions", <i>Journal of Molecular Recognition</i> , 1999; 12:371-389	
D	В8	LUBAN, Jeremy, "HIV-1 and Ebola virus: The getaway driver nabbed", <i>Nature Medicine</i> , December 2001; 7(12):1278:1280	
	B9	MARTIN-SERRANO, Juan, et al., "HIV-1 and Ebola virus encode small peptide motifs that recruit TSG101 to sites of particle assembly to facilitate egress", <i>Nature Medicine</i> , December 2001; 7(12):1313-1319	
U	B10	DEMIROV, Dimiter G., et al., "Overexpression of the N-Terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function", <i>PNAS</i> , January 22, 2002; 99(2):955-960	

Examiner Signature Date Considered 3)/8/0/

1

EL	INFOR					Complete if Known							
		MATION	Substitute for form 1449A/PTO						972,035				
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT							October 4, 2001  Daniel Albert WETTS Tendert al.				
	SIAIL												
	(4400.4		ata sa nacas			Group Art Unit Examiner Name			Myron G. HILL				
Sheet	(use a	1 1	ets as necess		1	Attorney Docke			1907.03				
Silect	-	<u> </u>		' '	<u>'</u>	- Autorney Booke	100.	100.00					
								· ·				<del>2</del>	
					U.S.	PATENT DOCU	MENTS_	-		Danna salumna		0	
Examiner Initials'	Cite	U.S. Patent Documents  Number Kind Code <sup>2</sup> (if known)			Name of P	Name of Patentee or Applicant Date of		Publication		Pages, columns, lines, Where Relevant			
	No. <sup>1</sup>				of Cited Documents		of Cited Document MM-DD-YYYY		Passages or Relevant Figures Appear				
	-												
	<u> </u>				·								
					EODEIG	SN PATENT DO	LIMENTS	<u> </u>					
		Fore	eign Patent Do	cumer		SIN FAILINI DOC	ONLIVE		·	Pages, Column	ns. Lines.	Т	
	Cite	Cite			Name of Patentee	Date of Publication of Cited Document		Where Relevant					
Initials	No.	Office	Number			•		MM-DD-Y		Passages or Relevant		1	
- N/	Δ1	<del>                                     </del>						11_28_2	2002	riguies Appeai		+	
Willi	AI	<u> </u>	y O 02/09*	13 14		Conen et al.	1	11-20-2	.002	L			
UN													
MA						41 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	DOCUM	=N15					
hig			111			n CAPITAL LETTERS		**		to) title of the	i		
Examiner Initials'	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number <sup>4</sup> VO 02/094	Kind ( (if kn	Code <sup>5</sup> A	Name of Patentee Applicant of Cited Docu  Cohen et al.	ments	of Cited Do MM-DD-\ 11-28-2	cument YYY	Where Rel	ev Re	ant levant	

\\Barrister\Intellectual Property\Patent Prosecution\1900-1999\1907\1907.03\1907.03 2003-09-19 SUPPL-IDS MM.doc